Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 387

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 387
---
urock                                                                                   |      2,033 |                                -520 |            1,513 |                           12 |                                    9 |                             1,580 |                             1,702 |
| Tzield                                                                                     |      2,714 |                                -375 |            2,339 |                           12 |                                   11 |                             2,405 |                                 — |
| Beyfortus                                                                                  |      2,288 |                                -201 |            2,087 |                           17 |                                   16 |                             1,870 |                               180 |
| Qunol                                                                                      |        790 |                                 -91 |              699 |                           10 |                                    8 |                               722 |                                 — |
| Total: principal marketed productsincl. Opella products presented in"Assets held for sale" |     68,753 |                             -53,958 |           14,795 |                              |                                      |                            15,927 |                            11,863 |
| Total: principal marketed productsexcl. Opella products presented in"Assets held for sale" |     60,214 |                             -48,212 |           12,002 |                              |                                      |                            13,055 |                             9,429 |

(a) Weighted averages. The amortization periods for these products vary between 1 and 25 years.

(b) Weighted averages.

(c) Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024

(see Note D.1.).

During 2023 , some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ALTUVIIIO (efanesoctocog alfa) which extends protection from bleeds and treats acute hemorrhages in people with hemophilia A. The main asset brought into service during 2022 was Enjaymo (sutimlimab-jome), a treatment for cold agglutinin disease.

| SANOFIFORM 20-F2024 | F-43 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Amortization of other intangible assets is recognized in the income statement within the line item Amortization of intangible

assets , except for amortization of software and other rights of an industrial or operational nature which is recognized in the

relevant classification of expense by